Background: Bipolar affective disorder (BPAD) and schizophrenia (SZ) are devastating psychiatric disorders that each affect about 1% of the population worldwide. Identification of new drug targets is an important step toward better treatment of these poorly understood diseases.
B ipolar affective disorder (BPAD) and schizophrenia (SZ) are common and devastating diseases of the human brain that have consistently been shown to be highly heritable (1) . It is likely that shared as well as nonshared genetic risk factors exist for these disorders (2) . Studies aimed at identification of genetic risk factors may thus gain power by including samples across diagnostic boundaries-provided that the identified risk factors are among the shared ones.
Recent large-scale genetic studies of BPAD and SZ have been very encouraging and revealed common variants that contribute to disease risk (3) (4) (5) (6) (7) (8) . Furthermore, rare disease-associated copy number variants (CNVs) have been reported for SZ (9) and BPAD (10) , but later work has suggested that this phenomenon may be limited to SZ and early-onset BPAD (11) . To tie rare CNVs to disease with certainty, evidence of segregation with disease in larger pedigrees would be of great value. In complex psychiatric disease, this approach is, however, strongly limited by the complex inheritance patterns, diagnostic uncertainty, and likely heterogeneity within extended pedigrees. To date, no CNV has been identified in either BPAD or SZ that shows segregation with disease in larger pedigrees.
The present study aimed at identifying rare but highly penetrant genetic risk factors, with an initial focus on BPAD. As an alternative hypothesis, samples from BPAD, SZ, and schizoaffective disorder (SA) were combined in the analysis. This analysis is more powerful due to a larger combined sample size and is justified by several recent reports indicating the presence of shared genetic factors for BPAD and SZ.
Highly penetrant CNVs, although not detected by microsatellite genotyping, were likely to be located in regions of linkage, and we therefore focused our efforts on those families that had shown the largest prior evidence for linkage in microsatellitebased linkage analyses.
Previously published linkage results on the BPAD families from the National Institute of Mental Health (NIMH) collection have included parametric and nonparametric analysis in four genotyping waves (12) , but no data had been made available regarding parametric scores in individual families. Thus, to identify the families with the highest parametric logarithm of the odds (LOD) scores, family-wise parametric linkage analysis of the entire NIMH bipolar waves 1 to 4 dataset (644 families) was carried out using several different models (dominant, recessive, nonparametric) based on the existing microsatellite data. Forty-eight families were then selected for our study (see Methods and Materials and Table S1 in Supplement 1 for details). A total of 277 DNA samples from these families was obtained and genotyped on the Illumina 610quad chip (Illumina, Inc., San Diego, California). CNVs were called from single nucleotide polymorphism (SNP) and CNV probe intensity data using PennCNV (http://www. openbioinformatics.org/penncnv/; [13] ), which has been shown to be conservative with regard to the number of CNVs called (14) .
In further stages of this study, we followed up on one apparently highly penetrant CNV from the family-based analysis. We investigated 4084 unrelated cases by the same CNV calling method. Finally, we combined our own data with evidence from publicly available datasets and carried out a pooled analysis including a total of 10,925 patients and 16,747 control subjects.
Methods and Materials

Selection, Genotyping, and CNV Calling of 48 BPAD Families for Investigation of Familial Disease-Linked CNVs
Forty-eight families (277 individuals) from the NIMH genetics initiative BPAD collection (http://www.nimhgenetics.org) were selected for genotyping (Table S1 in Supplement 1). Of these, 33 families were selected based on prior, microsatellite-based, LOD score evidence. Fifteen additional families were selected based on prior evidence of runs of homozygosity or Mendel errors in publicly available candidate gene polymorphism data (none of which included the MAGI1 or MAGI2 genes).
Forty-six of these families (269 individuals) described themselves as White, while two families reported Black ancestry. DNA samples were obtained from the cell and DNA repository at Rutgers University (Camden, New Jersey). Genotyping was performed using the Illumina Human 610quad chip at the SNP Technology Platform, Uppsala University, Sweden. Genotype data were successfully generated for 275 samples at 592,275 SNPs. Of the called SNPs, 99.4% had call rates greater than 95%. The mean SNP call rate was 99.8%. All successfully genotyped samples had call rates greater than 98%.
Several steps were carried out for quality control. In the first step, all samples that showed a standard deviation of the log R ratio (LRR) of more than .3 were re-genotyped on the same platform (n ϭ 52). All re-genotyped samples had standard deviations of less than .15 in the final data. Plots of the per-sample LRR and B allele frequency (BAF) for representative samples are shown in Figure S1 in Supplement 1.
Planned duplicates were removed, keeping the sample with the lower LRR standard deviation. Family relationships were validated based on identity by state and presence of unplanned duplicates was excluded (none were detected). Ethnicity was confirmed using principal component analysis. Copy number variants were called using PennCNV (13) with default parameters. Four duplications of entire chromosomes or chromosome arms were identified in the data that were likely cell-culture artifacts and thus removed before analysis. A total of 10,512 CNVs were called and included in the analysis.
For the initial CNV analysis, a cutoff was set at 10 kilobase (kb) minimum size for all included variation (7206 CNV calls passed this threshold). The relatively short minimum size, with its associated high false-positive CNV detection rate, was selected to increase sensitivity at the cost of specificity in this first, hypothesis-generating step of the analysis. A strict filter based on the database of genomic variants (DGV; version 8, July 2009; http://projects.tcag.ca/ variation/; [15] ) was then applied to exclude all CNVs identified in our material that overlapped with variation found in the general population.
To identify the strongest candidates for highly penetrant CNVs, all CNVs larger than 10 kb and not overlapping with known variation were ranked based on the number of affected individuals per family in which they were found. This scoring method was preferred over a LOD score based analysis for practical reasons, since LOD scores in CNV-containing regions are likely affected by erroneous genotypes in the corresponding genomic interval. Furthermore, even when CNVs are correctly called and recoded as genetic markers, repetitive sequences and inversions frequently present in the CNV interval may still affect linkage scores. Finally, a LOD score based analysis has a bias toward recessive loci, while our scoring method does not show such a bias. We thus decided to simply count the occurrences of the CNV in the affected individuals of each family and to rank the CNVs accordingly. A total of 5245 samples from 5134 patients were genotyped (108 samples were planned duplicates). The samples were genotyped in two batches using the Illumina Human1M-duo chip (Illumina, Inc.). In the first batch, a total of 3006 samples were genotyped. Genotype data were successfully generated for 2947 samples at 1, 152, 197 SNPs. In the second batch, a total of 2239 samples were genotyped. Genotype data were successfully generated for 2215 samples at 1,149,343 SNPs. In both batches, more than 99.5% of the called SNPs had call rates greater than 95%. All successfully genotyped samples had call rates greater than 98%. Hardy-Weinberg equilibrium tests were performed using Caucasian samples only. A total of 3017 SNPs in the first batch and 1952 SNPs in the second batch failed the Hardy-Weinberg equilibrium test (p value Ͻ 1e-4). In the total sample, genotype data were successfully generated on 5162 samples. The following quality control steps were performed to remove duplicated and/or problematic samples. First, gender discrepancies were examined using both the heterozygosity rate of the X chromosome SNPs and the call rate of the Y chromosome SNPs. Samples with discrepant and ambiguous sex information were excluded. Second, the relatedness of the genotyped samples was examined using pairwise identity by state. Third, ethnicity was checked using principal component analysis. Planned but not confirmed duplicates, as well as unplanned duplicates with discrepant phenotype data, were excluded from subsequent analyses. For each pair of samples that were planned and confirmed duplicates, unplanned duplicates with consistent phenotype data, or samples of related individuals, the sample with a smaller standard deviation of the LRR was retained. After the sample quality control, there were 4692 samples (3192 SZ, 377 SA, and 1123 BPAD) remaining. These samples were analyzed for CNV content using PennCNV with default parameters. A total of 608 samples were flagged due to their large standard deviations for LRR (Ͼ.2), their drifting BAF values, or their waviness factor values. Copy number variant calls were generated for the remaining 4084 samples (2826 SZ, 321 SA, and 937 BPAD).
cases and control subjects. Table 1 provides a summary of all studies and CNV calling methods included in our pooled analysis.
Statistical Analysis
Statistical analysis was carried out using R (19) version 2.9.2 (R Foundation for Statistical Computing, Vienna, Austria), unless otherwise stated. For the CNV-disease association, we used Fisher's exact test with a one-sided alternative hypothesis (alternative hypothesis: MAGI1 CNV frequency higher in cases than in control subjects; null hypothesis: MAGI1 CNV frequency lower in cases than in control subjects or equal). Statistical significance was defined as p Ͻ .05. Parametric linkage analysis in the NIMH families was performed with GENEHUNTER-PLUS (http://galton.uchicago.edu/ genehunterplu; [20] ). Relationships of individuals within the NIMH BPAD families were validated using graphical representation of relationship errors (21) .
Results
Stage I: Family-Based Analysis
All CNVs in the family material that were larger than 10 kb and not overlapping with DGV variation were ranked according to the number of affected individuals per family in which they were found. This approach is more robust to genotyping errors than a formal LOD score based analysis using SNP genotypes. Such errors are likely to be numerous in CNV-containing regions.
The highest-ranking CNV according to this procedure was a deletion in intron 1 of the MAGI1 gene, approximately 200 kb in length (chromosome 3:65,649,762-65,848,146; top red bars in Figure 1) . Figure 2 shows pedigree 11-158, in which the abovedescribed CNV was found in six out of six affected individuals (all affected were bipolar type 1). Data provided in Table 2 show that this CNV was detected with almost identical start and end points in the six affected members of this family. The parametric LOD score e The DGV database was used in the initial screen only. No MAGI1 or MAGI2 CNVs over 100 kb were seen. However, due to sample overlap, large variety of methods, and report criteria, these control subjects were omitted from the case-control analysis.
(dominant model) for this family, based on surrounding single nucleotide polymorphism data, was 1.14. This was slightly lower than the parametric LOD score of 1.26 in the original, microsatellitebased analysis. Table S4 in Supplement 1 provides basic demographic and clinical information of the mutation carriers.
The CNV ranking procedure described above was blind for location of identified CNVs (intragenic vs. intergenic regions) or gene function. It was, therefore, remarkable that the highest ranking CNV (six out of six affected individuals in one family) was located in the MAGI1 gene. The gene is located on chromosome 3p14 in a suggestive linkage region identified in several previous reports (22) (23) (24) (25) , and expression differences of MAGI1 in bipolar cases versus control subjects have recently been reported (22) . Furthermore, based on its function as a synaptic scaffolding molecule, MAGI1 is an excellent functional candidate gene for psychiatric disorders and interacts with a large number of previously implicated molecules (see Figure S2 and Table S5 in Supplement 1 for a summary).
Although identification of a seemingly highly penetrant deletion in MAGI1 was interesting, it was not possible to assess significance of this finding, mainly due to the nonrandom selection of families and the modest sample size. Identification of a CNV in MAGI1 was thus considered a hypothesis-generating step, and validation was necessary.
Further inspection of the NIMH families revealed presence of a second copy number event in the MAGI1 gene ( Figure 1 , Table 2,  and Table S4 in Supplement 1). This CNV was a duplication of approximately 160 kb, stretching from the promoter of MAGI1 across exon 1 and into the first intron (chromosome 3:65,877,457-66,036,767). The duplication was found in two out of three affected members of NIMH pedigree 11-130 (all affected were bipolar type 1; see Figure 2 for a pedigree drawing and Table S4 in Supplement 1 for demographic and clinical data).
Neither of the above-described CNVs was present in either the DGV or Children's Hospital of Philadelphia-CNV databases of common variation. However, due to the rare nature of their occurrence (2 out of 48 families), larger datasets needed to be investigated to establish significance.
Stage 2: CNV Discovery in Unrelated Samples
Additional support was sought through analysis of a large sample of unrelated cases. A sample of 1123 unrelated BPAD patients, 377 SA individuals, and 3192 SZ cases was available for analysis. Under the assumption that BPAD, SZ, and SA share some genetic risk factors, samples from all three disease groups can be analyzed together. Considering BPAD, SZ, and SA cases as one large joint case group maximizes the power to find risk factors that are shared across diagnostic boundaries, if such shared risk factors exist. As an alternative hypothesis, we therefore screened the extended dataset of BPAD, SZ, and SA cases for MAGI1 CNVs. A total of three CNVs larger than 100 kb were identified within MAGI1 in these samples (Figure 1 , Tables 1 and 2, and Table S4 in Supplement 1). One of these three CNVs was a deletion and the other two were duplications. All three CNVs were found in individuals diagnosed with SZ, located within the first intron and overlapped with the 200 kb deletion identified in the familial bipolar sample (Figure 1 ).
Stage 3: Pooled Analysis of Own and Publicly Available Data
Further supporting evidence was derived from publicly available case/control data, as well as reports of CNVs in normal populations (Figure 1, Tables 1 and 2) . Three CNVs over 100 kb were identified in cases from the International Schizophrenia Consortium (9) (26) . No MAGI1 CNVs were found in a control sample used in a recent autism study (27) . Neither were any CNVs present in 1274 autism cases. These cases were not included in the statistics of the present study, since they could be counted as cases in a further extension of the phenotype or as control subjects if the focus is on disease specificity of the identified MAGI1 mutations. Table 3 shows the results from the statistical tests for association carried out based on the pooled analysis described above. The initially identified MAGI1 deletion, which co-segregated with disease in the NIMH-BPAD family, was removed from all counts due to its role as the hypothesis-generating finding. We performed tests of association of MAGI1 CNVs with BPAD alone or in the extended sample of BPAD, SZ, and SA. Significant association (p Ͻ .05) was found in the extended sample.
During the literature review, it became evident that a previous study by Walsh et al. (17) had described a CNV in the closely related MAGI2 gene and identified a pathway including MAGI2 in which rare structural variants were overrepresented in schizophrenia. Presence of further CNVs in the MAGI2 gene in our samples and the public resources was therefore assessed.
One CNV in MAGI2 was found in our material of unrelated cases in one SZ patient (ClinTcnv4 in Tables 1 and 2 and Table S4 in Supplement 1). This deletion was very large (Ͼ1 Mb) and did not include any other genes except for MAGI2. The International Schizophrenia Consortium reported one further CNV event over 100 kb in MAGI2 in a schizophrenia patient. In the control samples, one large duplication (ϳ1 Mb) and one smaller (153 kb) had been described in MAGI2.
Discussion
CNV Detection and Validation
We here report results from a multistage approach for identification of rare, highly penetrant CNVs in psychiatric disease. For the initial screening part of this study, DNA derived from lymphoblastoid cells was used. It has been shown in several studies that such DNA may differ in its CNV contents from blood-derived DNA (13) . A major strength of the family-based approach (stage 1 of this study) is that the CNVs were found in several individuals of the same family and with virtually identical borders ( Figure 1 ). These CNVs are therefore extremely unlikely to be cell culture-derived artifacts. Large materials of unrelated cases and control subjects were then screened for further mutations in MAGI1. Given that no DNA from relatives was available for these samples, one advantage of our approach was that all further newly identified CNVs were detected in blood-derived DNA. Thus, any influence of cell culture artifacts on CNV data obtained in our laboratories can be excluded.
The 200 kb deletion in MAGI1 was further validated by the fact that it was present in the CNV data from the original NIMH Genetic Association Information Network study (10) , carried out on a different platform and using a different algorithm. Furthermore, we downloaded the NIMH Genetic Association Information Network data and re-analyzed it using a more permissive calling algorithm provided by PennCNV. The deletion was still seen with identical borders, while no further CNVs were seen in MAGI1 in control subjects (data not shown). The MAGI1 200 kb deletion can thus safely be regarded a true positive finding. One disadvantage of our study is that due to the large number of different sources from which the CNVs were reported, it was not possible to obtain DNA for independent validation of the CNV status in unrelated individuals with a different method. However, the raw data presented in Figure S1 in Supplement 1 and quality control measures presented in Table 2 suggest that the signal-to-noise ratio in the clinical trial derived samples was excellent. Copy number variants are clearly visible in the LRR as well as the BAF plots. All newly identified CNVs spanned more than 60 markers in the region (Table 2) . A recent study has shown that CNV calls larger than 20 markers become robust across platforms and algorithms (16) , and all of the calls reported herein are well above that threshold.
Copy number variants derived from published studies and included in the total counts have undergone standard quality control. MAGI1 case CNVs have been detected by five different laboratories, while two control CNVs were reported by the same laboratory. The large control CNV was identified in a cell culture derived sample, thus opening the possibility of a cell culture artifact. Five other laboratories did not see any CNVs over 100 kb in their control data. It is therefore unlikely that a bias toward CNV detection in one lab or a The first identified MAGI1 CNV in the NIMH sample was excluded from all CNV counts due to its role as hypothesis-generating step. Samples included in more than one study were only counted once. Forty-eight unrelated members of the NIMH families were included in the case counts.
b Fisher's exact test for association between MAGI1/MAGI2 CNVs and disease. p values are one-sided due to the prior hypothesis that CNVs were more common in cases.
on one platform has led to the excess of CNVs in cases as compared with control subjects.
While our results comprise an important step toward a better understanding of possible involvement of MAGI1 and MAGI2 in psychiatric disease, much larger samples (preferably blood derived) will be necessary to reach a reasonable estimate of the effect size and the variance explained.
Possible Role of MAGI1/MAGI2 in BPAD and SZ Etiologies
One major strength of the findings presented herein is the fact that the identified CNVs were confined to single genes, while previously identified CNV regions usually encompassed a large number of potential candidates, several of which may act together to cause disease (9, 28) . While such larger regions are likely to explain a larger part of the total variance, CNVs confined to single genes, if confirmed by others, may have a greater value in understanding disease pathways. Convergent evidence for an involvement of membrane-associated guanylate kinase genes in SZ etiology has recently been provided by an independent genome-wide study of de novo CNVs in SZ (29) .
The CNVs reported in this study include both gain and loss of gene segments. It has previously been shown that genomic deletions and duplications of a gene may have deleterious effects on gene function and lead to similar phenotypes. One example of this is the BRCA1 gene, screening of which for germline deletions and duplications is now routine clinical practice in families with high risk of breast and ovarian cancer (30) .
The MAGI1 gene encodes a postsynaptic scaffolding protein that interacts with a multitude of molecules that have been identified in the molecular pathology of BPAD and SZ, such as neuroligins (31), beta-catenin (32), the neuregulin receptor ErbB4 (33) , and glutamate receptors (34) . Figure S2 and Table S5 in Supplement 1 provide an overview of these interactions and their connections to other previously identified molecules in psychiatric genetics.
It is noteworthy that our genome-wide approach, which was not based on investigation of functional candidates, identified a gene that actually has been investigated as a SZ candidate gene in at least one earlier study (33) . In this earlier report, MAGI1 and MAGI2 were shown to interact with the neuregulin receptor ErbB4 and were assessed by means of genetic association. Nominally significant association of MAGI1 was identified, which, however, did not hold up after correction for multiple testing in that study.
Another link that ties MAGI1 to psychiatric phenotypes is its binding to neuroligins, which bind to neurexins. Deletions in neurexins and neuroligins have been identified in schizophrenia and autism (35, 36) , and it has, so far, been undetermined whether BPAD could also be caused by disruptions in this pathway (37) . Our data support this notion and suggest that BPAD be included in further neurexin-neuroligin-MAGI1/MAGI2 signaling pathway investigations.
With regard to treatment approaches in BPAD, it is noteworthy that MAGI1 has been shown to bind beta-catenin in several studies (32) . Beta-catenin is regulated by GSK3B, a gene that has consistently been shown to be regulated by lithium treatment (38) . Therefore, the glycogen synthase kinase 3-beta/catenin signaling pathway has been a primary target for new therapeutic strategies in BPAD. MAGI1 and beta-catenin appear to have similarly diverse roles in the cell: organization of postsynaptic proteins and cell-cell contact, as well as a role in the nucleus. For beta-catenin, it is well established that it has a function as a transcriptional co-regulator, while MAGI1 function in the nucleus remains to be understood.
Finally, MAGI1 has recently been shown to be a major target of viral proteins (39) , providing a possible link between prenatal viral exposure and neurodevelopmental brain diseases such as SZ and BPAD.
Our findings suggest that genome-wide linkage efforts in BPAD and SZ have not been entirely futile, since 3p14 has been identified as a suggestive linkage region in BPAD in several studies (23) (24) (25) and has also been reported as a region of interest for SZ (40) . Therefore, focused investigation of copy number variation in suggestive genomic linkage areas is warranted.
Samples from BPAD, SZ, and SA were combined for analysis in the present study. This is based on the assumption that shared genetic risk factors exist for these disorders, an idea that has recently received support from epidemiological as well as genomewide association data (1,7). Our results suggest that MAGI1 and MAGI2 may be rare disease genes in pathogenic pathways common to these disorders.
